Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Large Increase in Short Interest

Repare Therapeutics Inc. (NASDAQ:RPTX) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totaling 437,896 shares, an increase of 125.3% from the December 31st total of 194,336 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average daily volume of 984,565 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 984,565 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.1% of the shares of the company are short sold.

Repare Therapeutics Price Performance

Shares of RPTX stock traded up $0.02 during trading hours on Thursday, reaching $2.65. 1,219,900 shares of the company traded hands, compared to its average volume of 947,968. The firm has a 50-day moving average price of $2.38 and a 200 day moving average price of $1.94. The company has a market cap of $114.24 million, a P/E ratio of -1.57 and a beta of 0.97. Repare Therapeutics has a 12-month low of $0.89 and a 12-month high of $2.66.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings results on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to analysts’ expectations of $7.50 million. Sell-side analysts predict that Repare Therapeutics will post -2.04 EPS for the current year.

Wall Street Analyst Weigh In

RPTX has been the subject of a number of recent analyst reports. HC Wainwright decreased their target price on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday, December 22nd. Finally, TD Cowen lowered shares of Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On Repare Therapeutics

Institutional investors have recently bought and sold shares of the business. Rangeley Capital LLC purchased a new stake in shares of Repare Therapeutics during the second quarter worth about $494,000. Acadian Asset Management LLC boosted its stake in Repare Therapeutics by 35.6% in the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after purchasing an additional 168,230 shares during the period. Militia Capital Partners LP purchased a new stake in Repare Therapeutics during the 2nd quarter valued at approximately $166,000. Squarepoint Ops LLC bought a new stake in shares of Repare Therapeutics during the third quarter valued at approximately $115,000. Finally, XTX Topco Ltd bought a new position in shares of Repare Therapeutics during the second quarter worth $60,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.